Emerging PPARγ-Independent Role of PPARγ Ligands in Lung DiseasesReportar como inadecuado




Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

PPAR ResearchVolume 2012 2012, Article ID 705352, 13 pages

Review Article

Division of Pulmonary and Critical Care, Department of Medicine, University of Rochester School of Medicine and Dentistry, Box 692, Rochester, NY 14642, USA

The Lung Biology and Disease Program, University of Rochester School of Medicine and Dentistry, Box 692, Rochester, NY 14642, USA

Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, Box 692, Rochester, NY 14642, USA

Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Box 692, Rochester, NY 14642, USA

Department of Oncology, University of Rochester Medical Centre, USA

Received 9 January 2012; Revised 28 March 2012; Accepted 12 April 2012

Academic Editor: Virender Rehan

Copyright © 2012 Ajit A. Kulkarni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Peroxisome proliferator activated receptor PPAR-γ is a nuclear hormone receptor that is activated by multiple agonists including thiazolidinediones, prostaglandins, and synthetic oleanolic acids. Many PPARγ ligands are under investigation as potential therapies for human diseases. These ligands modulate multiple cellular pathways via both PPARγ-dependent and PPARγ-independent mechanisms. Here, we review the role of PPARγ and PPARγ ligands in lung disease, with emphasis on PPARγ-independent effects. PPARγ ligands show great promise in moderating lung inflammation, as antiproliferative agents in combination to enhance standard chemotherapy in lung cancer and as treatments for pulmonary fibrosis, a progressive fatal disease with no effective therapy. Some of these effects occur when PPARγ is pharmaceutically antagonized or genetically PPARγ and are thus independent of classical PPARγ-dependent transcriptional control. Many PPARγ ligands demonstrate direct binding to transcription factors and other proteins, altering their function and contributing to PPARγ-independent inhibition of disease phenotypes. These PPARγ-independent mechanisms are of significant interest because they suggest new therapeutic uses for currently approved drugs and because they can be used as probes to identify novel proteins and pathways involved in the pathogenesis or treatment of disease, which can then be targeted for further investigation and drug development.





Autor: Ajit A. Kulkarni, Collynn F. Woeller, Thomas H. Thatcher, Sesquile Ramon, Richard P. Phipps, and Patricia J. Sime

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados